AstraZeneca's Results From Japan Phase 3 Trial Of Acoramidis For Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Is Consistent With BridgeBio Pharma's ATTRibute-CM Phase 3 Trial, Including Survival, Cardiac-Related Hospitalizations
阿斯利康的日本阿科拉米德治療轉甲狀腺素介導澱粉樣心肌病（ATTR-CM）的3期試驗結果與BridgeBio Pharma的Atribute-CM 3期試驗一致，包括存活率、心臟相關住院治療